You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi, in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer (BTC). The Food and Drug Administration (Already a subscriber Login You have read all your free articles,…
Medivir AB’s board of directors plans to use the authorization given at the annual general meeting to repurchase class B company shares. The repurchases will be carried out in batches over time, but will conclude prior to the next annual general meeting. The execution of the repurchases will deAlready a…
MedImmune and Abpro have entered into a collaborative agreement to advance the development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF). The agreement is structured as a spin out, benefiting from both companies’ scientifAlready a subscriber Login You have read all your free articles,…
AstraZeneca and MSD have announced that the companies have received marketing authorisation from China’s National Medical Products Administration (NMPA) for Lynparza (olaparib) as a 1st-line maintenance treatment of adult patients with newly diagnosed advanced germline or somatic BRCA mutated (gBRAlready a subscriber Login You have read all your free articles,…
